Since the introduction of insulin as the first therapeutic agent in the treatment of diabetes [74] there has been no further advances in the introduction of novel products addressing the T1DM [39], in particular targeting the fasting state, which is highly governed by glucagon and results in high glycemic excursions in the patient [75]. This evidence concerns the gene GCG and diabetes mellitus.